GGrantIndex
Sort

64,565 grants matching drug discovery

The Neuroproteomics and Neurometabolomics Center on Cell-Cell Signaling

$987,731
Jonathan V. Sweedler · University Of Illinois At Urbana-Champaign · P30 · FY2014 · DA

Efficient patient-specific cell generation by image-guidance

$987,686
Shih-Jong J Lee · Drvision Technologies, Llc · R44 · FY2012 · HL

Optimization of novel pyranopyridine efflux pump inhibitors

$987,681
Timothy J Opperman · Microbiotix, Inc · R44 · FY2019 · AI

Developmental Biology and Solid Tumor

$987,656
Richard James Gilbertson · St. Jude Children'S Research Hospital · P30 · FY2018 · CA

Developmental Biology and Solid Tumor

$987,654
Richard James Gilbertson · St. Jude Children'S Research Hospital · P30 · FY2017 · CA

Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of

$987,616
Stig K. Hansen · Carmot Therapeutics, Inc. · R44 · FY2013 · CA

Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes

$987,570
Ward Peterson · Symberix, Inc. · R44 · FY2019 · CA

Preclinical development of Novo29, a new antibiotic

$987,424
Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2020 · AI

The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) Project 2: Preclinical Model for Antiepileptogenic Therapy Screening in Post-traumatic Epilepsy

$987,181
Aristea S Galanopoulou · University Of Southern California · U54 · FY2019 · NS

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

$987,000
Andrea Califano · Columbia University Health Sciences · R35 · FY2022 · CA

Pathobiology of Neurodegeneration in C9ORF72 Repeat Expansion

$986,853
Leonard Petrucelli · Mayo Clinic Jacksonville · P01 · FY2017 · NS

Pathobiology of Neurodegeneration in C9ORF72 Repeat Expansion

$986,853
Leonard Petrucelli · Mayo Clinic Jacksonville · P01 · FY2018 · NS

Biological And Biochemical Characterization Of Sigma Receptors

$986,688
Tsung-Ping Ping Su · National Institute On Drug Abuse · ZIA · FY2016 · DA

Low-Cost Platform for Ultrasensitive Fluorescent Immunoblot

$986,651
Scott L Crick · Auragent Bioscience, Llc · R44 · FY2024 · GM

Therapy Against Recalcitrant C. albicans Infection

$986,559
Thomas A Dahl · Arietis · R44 · FY2010 · AI

Targeting Epigenetic Circuits in B-Cell Lymphomas

$986,490
Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2019 · CA

Drug Discovery from Slow Growing and Rare Microbial Species

$986,467
Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R44 · FY2014 · AI

Development and Preclinical Applications of Pancreatic Adenocarcinoma Models

$986,350
Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

CONUS PEPTIDES AND THEIR RECEPTOR TARGETS

$986,268
University Of Utah · P01 · FY2000 · GM

Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance

$986,128
Bryan E. Welm · University Of Utah · U01 · FY2020 · CA

Leveraging natural phenotypic variations of heterogenous ALS populations-in-a-dish to enable scalable drug discovery

$986,054
Justin Kawika Ichida · University Of Southern California · R01 · FY2024 · NS

Center for Computational Mass-Spectrometry

$985,859
Pavel A Pevzner · University Of California, San Diego · P41 · FY2008 · RR

KL4 Surfactant to Mitigate Radiation-Induced Lung Injury

$985,783
Robert Segal · Windtree Therapeutics, Inc. · R44 · FY2016 · AI

Biophysical mechanisms of gating and modulation in voltage-gated ion channel superfamily

$985,622
Baron Chanda · Washington University · R35 · FY2022 · NS

Novel Small-Molecule Therapies for CF

$985,620
Alan S Verkman · University Of California, San Francisco · P30 · FY2018 · DK